SWK — Q2 2025 Earnings Presentation
23 slides from SWK's earnings presentation, Aug 14, 2025
Slide 1: Collaborative Approach to Life Science Financing Shareholder Presentation 2Q25
1 Collaborative Approach to Life Science Financing Shareholder Presentation 2Q25 | August 2025
Slide 2: Forward-looking and Cautionary Statements
2 Forward-looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federal securiti
Slide 3: SWK Holdings - Overview
SWK Holdings - Overview 3 Underserved, High- Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial-stage healthcare companies and royalty owners • SWK targets $5M to $25M financings, a market niche that is less competitive and gen
Slide 4: Why Life Science Finance?
4 Why Life Science Finance? Tap into underlying demand that is pervasive, growing, and minimally correlated with economic cycles • Healthcare spend is large and increasing, representing 20% of U.S. GDP; forecast to grow at a 5% CAGR through 20301 • Sector has demonstrated durability as S&P 500 sales
Slide 5: Corporate Milestones
5 Corporate Milestones 2019 17th partner exit realized, bringing the weighted avg. IRR on all exits to 20% Acquired MOD3 Pharma Ended year with $178.7M investment assets 2020 Uplisted to Nasdaq and added to Russell 2000 Index Ended year with $212.5M investment assets 2022 Reconstituted B
Slide 6: Second Quarter 2025 Recap
Second Quarter 2025 Recap 6CONFIDENTIAL CORPORATE UPDATES FINANCE RECEIVABLES UPDATES • In 2Q25, SWK repurchased 147K shares of stock for a total cost of $2.2M • During 2025 monetized performing royalty portfolio for $51.3M • In May, paid $49.1M ($4.00/share) dividend • In July, divested MOD3 Pharma
Slide 7: Finance Portfolio Overview: 2Q25
7 Finance Portfolio Overview: 2Q25 1) Includes public company warrants and shares; private warrants carried at zero value 2) Excludes warrants and equity. 3) Based on Gross Finance Receivables balance 4) As of August 2025 • Gross Finance Receivables: $246.4M • Gross Total Investment Assets: $251.6M1
Slide 8: Financial Snapshot
8 Financial Snapshot 1) Eliminates provision for income taxes, MOD3 intangibles amortization, and non-cash mark-to-market changes on warrant assets and equity securities—see reconciliation on subsequent pages. $279.9 $280.3 $288.7 $246.5 $21.80 $22.43 $23.45 $20.23 2022 2023 2024 2Q25 SWK Stockholde
Slide 9: Attractive Portfolio Yields: Effective Yields
9 Attractive Portfolio Yields SWK Targets Low-to-Mid Teens Effective Yields1 2Q25 Finance Segment Effective Yield was 14.1% 1) Effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition policies, if all payments are received pursuant to the
Slide 10: Attractive Portfolio Yields: Realized vs. Effective Yield
14.3% 13.9% 15.5% 14.5% 14.0% 14.4% 14.2% 14.6% 14.6% 15.5% 14.4% 14.1% 17.5% 11.0% 15.3% 15.4% 14.7% 14.1% 15.2% 15.4% 13.8% 14.7% 15.5% 14.3% 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 Realized Yield vs. Effective Yield1 (at end of period) Effective Yield Realized Yield 10 Attract
Slide 11: Current Structured Credit Portfolio
Current Structured Credit Portfolio Biotricity 12.27.2021 $12.0 million Structured Credit NeoLight 02.17.2023 $5.0 million Structured Credit 11 4WEB Medical 07.01.2021 $20.0 million Structured Credit eTon Pharmaceuticals 11.14.2019 $30.0 million1 Structured Credit Nicoya 10.13.2023 $8.5 million1 Str
Slide 12: Portfolio Exits: Investments, MOIC and IRR
($s in Ms) Date Cash Investments # Security Invested Paid Off Invested Received MOIC IRR Exited Via Nautilus 1 Loan Dec-12 Dec-13 6.4$ 8.5$ 1.3x 34% Strategic Parnell I 2 Loan Jan-14 Jun-14 10.0 11.0 1.1x 24% Refinance Response 3 Loan Jul-14 Oct-15 12.6 6.1 0.5x (47%) Strategic PDI 4 Loan Oct-14 Dec
Slide 13: Portfolio Realizations to Strategic Buyers
13 Portfolio Realizations to Strategic Buyers Non-workout realizations to strategic buyers transacted at a 26% LTV of SWK’s original loan value 79% of businesses were not profitable at time of sale, validating SWK’s revenue and IP-based underwriting methodology Two of four workouts exited to s
Slide 14: SWK Sourcing
14 SWK Sourcing • Cultivates and maintains a diverse array of longstanding, proprietary deal sources • Consistently sources over 100 actionable investment opportunities per year • Maintains disciplined “look-to-book” ratio of approximately 2-3% Intermediated 12% Hybrid 50% Proprietary 38% 2024 Total
Slide 15: Financing Structures
Financing Structures 15 Product Acquisition • Primarily first lien, senior secured, floating rate loans • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commercialization and M&A Hybrid Financing Synthet
Slide 16: Historical Financing: Narcan Royalty
Historical Financing: Narcan Royalty 16 OPPORTUNITY SOLUTION • Opiant is a publicly-traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation – Novel formulation has a faster time to onset and more convenient and safer administration • Opiant need
Slide 17: Historical Financing: Galil Medical
Historical Financing: Galil Medical 17 OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash-flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force • In De
Slide 18: Leadership Team
18 Leadership Team Jody Staggs President and CEO • Joined in 2015 • Co-founded PBS Capital Management, predecessor to SWK • Prior to PBS, served as Senior Portfolio Analyst at Highland Capital Management • Investing experience in multiple asset classes John D. Tamas Director of Underwriting • Joined
Slide 19: Why Invest in SWKH – Attractive Risk Reward Scenario
Why Invest in SWKH – Attractive Risk Reward Scenario 19 Shareholder Return Focused • SWK story is not widely known, having uplisted to Nasdaq without benefit of traditional IPO • Analyst coverage and proactive investor relations effort have helped to increase SWK’s visibility • With a Book Value per
Slide 20: Reconciliation of Non-GAAP Adjusted Net Income
20 Reconciliation of Non-GAAP Adjusted Net Income The following table provides a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated net income (Non-GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non-cash mar
Slide 21: Reconciliation of Non-GAAP Specialty Finance Net Income
21 Reconciliation of Non-GAAP Specialty Finance Net Income The following table provides a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non-GAAP adjusted net income for the specialty finance business for the periods denote
Slide 22: Contact Information
22 Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: Alliance Advisors IR • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: [email protected] • Office address: 5956 Sherry Lane, Unit 650 Dallas, TX 75225 • Website: www.swkhold.com • Susan Xu: ̶ Phone: 778.323.0959 ̶ Em
Slide 23: Collaborative Approach to Life Science Financing
23 Collaborative Approach to Life Science Financing